20 May 2009, Cambridge, UK – BioWisdom Ltd (BioWisdom), a market leader in delivering healthcare intelligence to the pharmaceutical industry, today announces that its Safety Intelligence Program has been awarded a prestigious “Best Practices” award at the recent Bio-IT World Life Sciences Conference and Expo in Boston.

This award recognises the implementation of the Safety Intelligence Program at AstraZeneca. AstraZeneca partnered with BioWisdom for the Safety Intelligence Program in July 2007, to enhance its ability to predict and understand safety related issues early in the discovery process. The Safety Intelligence Program applies state-of-the-art technology and methodology to deliver an assertional meta-data solution that semantically harnesses publicly accessible information. The Program is used to support drug safety risk assessment at various stages of the drug discovery process.

“We are honoured by this award and the recognition that Bio-IT World Life Sciences Conference and Expo has given the implementation of our Safety Intelligence Program by AstraZeneca,” said BioWisdom’s Chief Scientific Officer, Dr Julie C. Barnes. “We applaud AstraZeneca for the innovative application of the Program and the engineering of new business processes that result from its use”

“We’re delighted to win this award and honoured that our work with BioWisdom has been recognized by the broader community” said Dr David Cook, Global Safety Assessment, AstraZeneca. “We’re continuing to develop our strategies for improving predictive toxicology through initiatives like the Safety Intelligence Program and look forward to continuing our strong collaboration with BioWisdom in this important area.”

Bio-IT World is an industry-leading publication relating to enabling technologies that drive biomedical research and drug development, with an emphasis on predictive biology, drug discovery informatics, personalised medicine, and clinical trials. Bio-IT World’s Best Practices Awards Program, established in 2003, recognizes academic and industrial organisations for outstanding examples of innovation and collaboration in the deployment of technologies, and novel business strategies that will advance drug discovery, biomedical research and clinical trials.  In this year’s awards, there were a record 72 submissions for a total of 10 awards. The Safety Intelligence Program won the Editor’s Choice Award. For more information on Bio-IT World, please visit: www.bio-itworld.com. For more information on The Life Sciences Conference and Expo, please visit: http://www.bio-itworldexpo.com/.

-Ends-

Notes to Editors
ABOUT BIOWISDOM LTD BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development. For more information, please visit www.biowisdom.com.

Tags: AstraZeneca, Award, Best practice, Intelligence, safety, SIP, toxicology

This entry was posted on Wednesday, May 20th, 2009 at 5:21 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.